Țară: Regatul Unit
Limbă: engleză
Sursă: MHRA (Medicines & Healthcare Products Regulatory Agency)
Clonidine hydrochloride
Glenwood GmbH
C02AC01
Clonidine hydrochloride
150microgram/1ml
Solution for injection
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050200; GTIN: 5012816025523
PACKAGE LEAFLET: INFORMATION FOR THE USER CATAPRES ® AMPOULES 150 MICROGRAMS IN 1 ML SOLUTION FOR INJECTION (clonidine hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets troublesome or serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What CATAPRES Ampoules are and what they are used for 2. Before you receive CATAPRES Ampoules 3. How CATAPRES Ampoules will be given 4. Possible side effects 5. How to store CATAPRES Ampoules 6. Further information 1. WHAT CATAPRES AMPOULES ARE AND WHAT THEY ARE USED FOR The name of your medicine is CATAPRES Ampoules 150 micrograms in 1 ml Solution for Injection (called CATAPRES Ampoules in this leaflet). Your medicine is a solution for injection. CATAPRES Ampoules contain a medicine called clonidine. This belongs to a group of medicines called antihypertensives. CATAPRES is used to lower high blood pressure in cases of hypertensive crisis (a rapid rise in blood pressure that needs treating straight away). 2. BEFORE YOU RECEIVE CATAPRES AMPOULES YOU SHOULD NOT BE GIVEN CATAPRES AMPOULES IF: • You are pregnant, likely to get pregnant or are breast-feeding • You are allergic (hypersensitive) to clonidine or any of the other ingredients of CATAPRES (see section 6: Further information) • You have a slow heart rate due to heart problems • You are under 18 years old You should not receive this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before having CATAPRES Ampoules. TAKE SPECIAL CARE WITH CATAPRES AMPOULES Check with your doctor or pharmacist before having CATAPRES if: • You have Raynaud’s disease (a problem wi Citiți documentul complet
OBJECT 1 CATAPRES AMPOULES Summary of Product Characteristics Updated 25-Sep-2017 | Boehringer Ingelheim Limited 1. Name of the medicinal product Catapres Ampoules 150 micrograms in 1 ml Solution for Injection. 2. Qualitative and quantitative composition Each 1 ml ampoule contains clonidine hydrochloride 150 micrograms. For excipients, see 6.1. 3. Pharmaceutical form Solution for injection. Clear, colourless solution. 4. Clinical particulars 4.1 Therapeutic indications Catapres is indicated for the treatment of hypertensive crises. 4.2 Posology and method of administration Adults, including the elderly: In hypertensive crises 150 to 300 micrograms (1 to 2 ampoules) should be given by slow intravenous injection. This dose may be repeated up to a maximum of 750 micrograms (5 ampoules) in a 24 hour period. Patients undergoing anaesthesia should continue their Catapres treatment before, during and after anaesthesia using oral or intravenous administration according to individual circumstances. Intravenous injection of Catapres should be given slowly over 10-15 minutes to avoid a possible transient pressor effect. Catapres injection solution is compatible with 0.9% sodium chloride solution and with 5% Dextrose solution. _PAEDIATRIC POPULATION:_ There is insufficient evidence for the application of clonidine in children and adolescents younger than 18 years. Therefore the use of clonidine is not recommended in paediatric subjects under 18 years. _RENAL INSUFFICIENCY:_ Dosage must be adjusted - according to the individual antihypertensive response which can show high variability in patients with renal insufficiency - according to the degree of renal impairment 4.3 Contraindications Catapres should not be used in children (please refer to section 4.4 Special Warnings and Precautions for Use) or in patients with known hypersensitivity to the active ingredient or other components of the product, and in patients with severe bradyarrhythmia resulting from either sick sinus syndrome or AV block of 2nd or 3rd degree. 4.4 Speci Citiți documentul complet